- The acquisition was completed on September 30, 2025.
- The Leverkusen plant complies with cGMP standards and employs about 150 staff.
- Terumo plans to complete new production lines at the Kofu factory by the end of 2025.
- The plant will offer fill & finish services for vials and polymer prefillable syringes.
Acquisition Completion
Terumo Corporation has finalized the acquisition of a Drug Product Plant and Quality Control Laboratory from WuXi Biologics in Leverkusen, Germany, with the transaction closing on September 30, 2025.
Facility and Services
The Leverkusen plant features state-of-the-art facilities compliant with current Good Manufacturing Practice (cGMP) standards and employs approximately 150 skilled professionals. Terumo will offer fill & finish services for vials and polymer prefillable syringes, including device assembly.
Expansion Plans
Terumo is expanding its global operations, with new production lines being installed at the Kofu factory in Japan, scheduled for completion by the end of 2025. This expansion aligns with the growing demand for CDMO services, particularly in Europe and the United States.
Strategic Focus
Terumo specializes in pharmaceutical primary containers and drug delivery devices, utilizing polymer materials optimized for pharmaceutical applications. The company is also active in the CDMO space for combination products that integrate pharmaceuticals and medical devices.
